Abstract
Naturally occurring heavy chain antibodies (HCAbs) in Camelidae species were a surprise discovery in 1993 by Hamers et al. Since that time, antibody fragments derived from HCAbs have garnered considerable attention by researchers and biotechnology companies. Due to their biophysico-chemical advantages over conventional antibody fragments, camelid single-domain antibodies (sdAbs, VHHs, nanobodies) are being increasingly utilized as viable immunotherapeutic modalities. Currently there are multiple VHH-based therapeutic agents in different phases of clinical trials in various formats such as bi- and multivalent, bi- and multi-specific, CAR-T, and antibody-drug conjugates. The first approved VHH, a bivalent humanized VHH (caplacizumab), was approved for treating rare blood clotting disorders in 2018 by the EMA and the FDA in 2019. This was followed by the approval of an anti-BCMA VHH-based CAR-T cell product in 2022 (ciltacabtagene autoleucel; CARVYKTI™) and more recently a trivalent antitumor necrosis factor alpha-based VHH drug (ozoralizumab; Nanozora®) in Japan for the treatment of rheumatoid arthritis. In this chapter we provide protocols describing the latest developments in isolating antigen-specific VHHs including llama immunization, construction of phage-displayed libraries, phage panning and screening of the soluble VHHs by ELISA, affinity measurements by surface plasmon resonance, functional cell binding by flow cytometry, and additional validation by immunoprecipitation. We present and discuss comprehensive, step-by-step methods for isolating and characterization of antigen-specific VHHs. This includes protocols for expression, biotinylation, purification, and characterization of the isolated VHHs. To demonstrate the feasibility of the entire strategy, we present examples of VHHs previously isolated and characterized in our laboratory.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Murphy KM, Weaver C (2016) Janeway’s immunobiology: ninth international, Student edn. Garland Science
Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ et al (2020) Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci 27(1):1
Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR (1994) Making antibodies by phage display technology. Annu Rev Immunol 12:433 –455
Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB et al (1993) Naturally occurring antibodies devoid of light chains. Nature 363(6428):446–448
Flajnik MF, Kasahara M (2010) Origin and evolution of the adaptive immune system: genetic events and selective pressures. Nat Rev Genet 11(1):47–59
Muyldermans S (2013) Nanobodies: natural single-domain antibodies. Annu Rev Biochem 82:775 –797
Nguyen VK, Hamers R, Wyns L, Muyldermans S (2000) Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire. EMBO J 19(5):921–930
Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM et al (1988) Single-chain antigen-binding proteins. Science 242(4877):423–426
Skerra A, Pluckthun A (1988) Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240(4855):1038–1041
McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348(6301):552–554
Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S (1997) Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 414(3):521–526
Muyldermans S (2021) Applications of nanobodies. Annu Rev of Anim Biosci 9:21
Arbabi-Ghahroudi M (2017) Camelid single-domain antibodies: historical perspective and future outlook. Front Immunol 8:1589
Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M et al (2009) Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol 198(3):157–174
Holliger P, Winter G (1993) Engineering bispecific antibodies. Curr Opin Biotechnol 4(4):446–449
McComb S, Nguyen T, Shepherd A, Henry KA, Bloemberg D, Marcil A et al (2022) Programmable attenuation of antigenic sensitivity for a Nanobody-based EGFR chimeric antigen receptor through hinge domain truncation. Front Immunol 13:864868
Henry KA, Tanha J, Hussack G (2015) Identification of cross-reactive single-domain antibodies against serum albumin using next-generation DNA sequencing. Protein Eng Des Sel 28(10):379–383
Chakravarty R, Goel S, Cai W (2014) Nanobody: the “magic bullet” for molecular imaging? Theranostics 4(4):386–398
Trempe F, Rossotti MA, Maqbool T, MacKenzie CR, Arbabi-Ghahroudi M (2022) Llama DNA immunization and isolation of functional single-domain antibody binders. Methods Mol Biol 2446:37 –70
Rossotti MA, van Faassen H, Tran AT, Sheff J, Sandhu JK, Duque D et al (2022) Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models. Commun Biol 5(1):933
Baral TN, MacKenzie R, Arbabi GM (2013) Single-domain antibodies and their utility. Curr Protoc Immunol 103:2 17 1-2 57
Arbabi-Ghahroudi M, To R, Gaudette N, Hirama T, Ding W, MacKenzie R et al (2009) Aggregation-resistant VHs selected by in vitro evolution tend to have disulfide-bonded loops and acidic isoelectric points. Protein Eng Des Sel 22(2):59–66
Rossotti MA, Henry KA, van Faassen H, Tanha J, Callaghan D, Hussack G et al (2019) Camelid single-domain antibodies raised by DNA immunization are potent inhibitors of EGFR signaling. Biochem J 476(1):39–50
Li Y, Sousa R (2012) Novel system for in vivo biotinylation and its application to crab antimicrobial protein scygonadin. Biotechnol Lett 34(9):1629–1635
Maniatis T, Fritsch EF, Sambrook J, Sambrook J (1989) Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory
Hussack G, Arbabi-Ghahroudi M, Mackenzie CR, Tanha J (2012) Isolation and characterization of Clostridium difficile toxin-specific single-domain antibodies. Methods Mol Biol 911:211 –239
Arbabi-Ghahroudi M, Tanha J, MacKenzie R (2009) Isolation of monoclonal antibody fragments from phage display libraries. Methods Mol Biol 502:341 –364
Hussack G, Arbabi-Ghahroudi M, van Faassen H, Songer JG, Ng KK, MacKenzie R et al (2011) Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem 286(11):8961–8976
Rossotti MA, Pirez M, Gonzalez-Techera A, Cui Y, Bever CS, Lee KS et al (2015) Method for sorting and pairwise selection of nanobodies for the development of highly sensitive sandwich immunoassays. Anal Chem 87(23):11907–11914
Hussack G, Ryan S, van Faassen H, Rossotti M, MacKenzie CR, Tanha J (2018) Neutralization of Clostridium difficile toxin B with VHH-fc fusions targeting the delivery and CROPs domains. PLoS One 13(12):e0208978
Henry KA, van Faassen H, Harcus D, Marcil A, Hill JJ, Muyldermans S et al (2019) Llama peripheral B-cell populations producing conventional and heavy chain-only IgG subtypes are phenotypically indistinguishable but immunogenetically distinct. Immunogenetics 71(4):307–320
Wernery U (2001) Camelid immunoglobulins and their importance for the new-born—a review. J Vet Med B Infect Dis Vet Public Health 48(8):561–568
Kabat EANIoHCU (1991) Sequences of proteins of immunological interest. U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda
Barbas CF, Barbas CF, Burton DR, Scott JK, Silverman GJ (2001) Phage display: a laboratory manual. Cold Spring Harbor Laboratory Press
Acknowledgments
This work was supported by the National Research Council of Canada, Human Health Therapeutic Research Center. We gratefully acknowledge the excellent assistance of Sonia Leclerc for DNA sequencing.
Conflict of Interest Statement
The authors have no conflicts of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Rossotti, M.A., Trempe, F., van Faassen, H., Hussack, G., Arbabi-Ghahroudi, M. (2023). Isolation and Characterization of Single-Domain Antibodies from Immune Phage Display Libraries. In: Hust, M., Lim, T.S. (eds) Phage Display. Methods in Molecular Biology, vol 2702. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3381-6_7
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3381-6_7
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3380-9
Online ISBN: 978-1-0716-3381-6
eBook Packages: Springer Protocols